Protalix BioTherapeutics (PLX) Gross Profit (2010 - 2026)

Protalix BioTherapeutics' Gross Profit history runs 17 years deep, the most recent figure standing at $29.6 million for Q1 2026.

• In Q1 2026, Gross Profit rose 1432.49% year-over-year to $29.6 million; the TTM figure through Mar 2026 stood at $53.4 million (up 78.93% YoY), while the FY2025 annual figure was $25.8 million, down 11.45% from the prior year.
• Gross Profit was $29.6 million for Q1 2026 at Protalix BioTherapeutics, up from $4.5 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $29.6 million in Q1 2026 to a low of $1.1 million in Q1 2024.
• Historically, Gross Profit has averaged $9.1 million across 5 years, with a median of $6.5 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Gross Profit plunged 86.11% in 2024, then soared 1432.49% in 2026.
• A 5-year view of Gross Profit shows it stood at $6.2 million in 2022, then slumped by 73.79% to $1.6 million in 2023, then soared by 779.26% to $14.3 million in 2024, then slumped by 68.58% to $4.5 million in 2025, then soared by 557.85% to $29.6 million in 2026.
• The last three Gross Profit figures came in at $29.6 million (Q1 2026), $4.5 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.